With the potential to launch as many as six new products or new indications for existing products in 2003, dependent on clinical success and regulatory approval, we are very well positioned to continue to deliver strong results.

Investors have been very patient with the biotech industry, which has been one of the biggest money-losing industries in the history of mankind. The cumulative loss by this industry from its inception in 1976 is nearing $100 billion.

Our solid first-quarter performance is in line with our expectations for the quarter and demonstrates progress towards achieving our financial goals for the year. We continue to remain focused on preparing for potential new product launches in 2003.

Our performance continues to be driven by robust sales of our innovative oncology products which have helped nearly double our revenues in a three-year time period.

This is an old issue and one on which we took corrective action back in 1994.

The stores are under a contract with a potential buyer. The projected settlement is for the end of April.